Damora (DMRA) CEO Jennifer Jarrett Buys 12,500 Shares

What Happened
Jennifer Jarrett, President, CEO and a director of Damora Therapeutics (DMRA), purchased 12,500 ordinary shares in an open-market transaction on September 25, 2026. The reported weighted-average price was $20.23 per share, for a total cash outlay of approximately $252,875. This was a personal purchase (transaction code P), which investors often view as a more informative, potentially bullish signal than routine sales.

Key Details

• Transaction date: 2026-09-25; Form 4 filed: 2026-09-28 (filed within the typical two-business-day Form 4 deadline).
• Price reported: weighted average $20.23; purchase prices ranged from $20.10 to $20.40 (footnote states multiple trades and offers to provide per-price breakdown on request).
• Shares purchased: 12,500; total value ≈ $252,875.
• Shares owned after transaction: total post-transaction common shares not specified in the summary provided; filing notes inclusion of 500,000 restricted stock units (RSUs) previously granted to the reporting person.
• Notable footnotes: F1 — open-market purchases with personal funds; F2 — weighted-average price with a stated price range and availability of per-trade details; F3 — 500,000 RSUs included in reported holdings.

Context
This was a cash purchase on the open market (not an option exercise or award settlement). RSUs noted in the filing represent rights to receive shares at settlement and are included in reported holdings; they are distinct from the open-market shares just bought. The filing is factual and does not state a motive; purchases by executives can be interpreted by some investors as a positive signal but do not guarantee future company performance.